IPSC
Century Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.47
close · 2026-10-30
value
30
cheaper than peers30
quality
46
stronger fundamentals46
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.14× | 74 |
| earnings yield, latest year | -9.5% | 73 |
| cash flow yield, 3 years ago | -6.2% | 64 |
| cash flow yield, 1 year ago | -41.4% | 29 |
| cash flow yield, latest year | -39.3% | 29 |
| earnings yield, 3 years ago | -154.4% | 27 |
| cash flow yield, 2 years ago | -38.4% | 27 |
| earnings yield, 2 years ago | -156.5% | 22 |
| earnings yield, 1 year ago | -109.5% | 21 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -49.7% | 64 |
| operating margin | 0.0% | 50 |
| debt to equity | 16.6% | 32 |
3 of 4 measures available
Facts
| market cap | $266M |
| free cash flow | -$50.4M |
| employees | 78 |
| first trade | 2021-06-18 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.14 | -1.61 | -2.30 | -2.27 |
| free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M |
| net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M |
| revenue | $109.2M | $6.6M | $2.2M | $5.2M |
| unusual items | -$6.8M | -$4.3M | -$21.4M | -$10.0M |